Federal Register Notice: FDA is reopening until 10/19/10 the comment period for the notice of public meeting published in the 4/20 Federal Register that took place 5/27-28 to solicit input on developing Risk Evaluation and Mitigation Strategies (REMS) for certain opioid drugs. The drugs include long acting and extended release brand name and generic products that are formulated with the following active ingredients: Fentanyl, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. To view this notice, click here.